[ad_1]
A new pilot study has demonstrated the possibility of using molecular markers of tumors as the basis for selecting chemotherapeutic agents to use in patients with metastatic pancreatic cancer. Based on these promising results, a larger Phase II clinical trial was initiated, using molecular biomarkers to guide the selection of second-line therapies. The design, results and implications of the initial pilot study are presented in Pancreatic cancer journal, a peer-reviewed, peer-reviewed publication by Mary Ann Liebert, Inc., publishers.
"A pilot test of custom molecular therapy for patients with metastatic pancreatic ductal adenocarcinoma" was co-authored by Michael Pishvaian, MD, PhD, Georgetown University, Washington, DC and his colleagues at the University of New York. Wayne State University, Detroit, Michigan, Georgetown University and Thomas Jefferson University, Philadelphia, PA.
The researchers designed a composite treatment algorithm based on three established predictive markers of the response to chemotherapy. They tested the presence of these markers in tumor biopsies and, depending on the results, badigned the patients to treatment with two chemotherapeutic agents that could cause a response. The researchers reported promising progression-free survival and overall survival, with a partial response in 28% of patients and stable disease in 50% at the end of the study.
Source:
Mary Ann Liebert, Inc.
Journal reference:
Pishvaian, M.J. et al. (2019) Pilot trial of a tailor-made molecular treatment for patients with metastatic pancreatic ductal adenocarcinoma. Pancreatic cancer journal. doi.org/10.1089/pancan.2019.0003.
[ad_2]
Source link
